Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851455 | 1.00 | NR1H2 (0.34) | NR1H2ALDH1A1FKBP1A | |
| SCHEMBL584023 | 0.86 | NR1H2 (0.43) | NR1H2ALDH1A1FKBP1A | |
| SCHEMBL584186 | 0.86 | NR1H2 (0.43) | NR1H2ALDH1A1FKBP1A | |
| SCHEMBL1914062 | 0.86 | NR1H2 (0.43) | NR1H2ALDH1A1FKBP1A | |
| SCHEMBL1914060 | 0.86 | NR1H2 (0.43) | NR1H2ALDH1A1FKBP1A | |
| SCHEMBL584853 | 0.83 | NR1H2 (0.48) | NR1H2 | |
| SCHEMBL3847760 | 0.83 | NR1H2 (0.48) | NR1H2 | |
| SCHEMBL584852 | 0.83 | NR1H2 (0.48) | NR1H2 | |
| SCHEMBL3951305 | 0.83 | ABCB1 (0.34) | NR1H2 | |
| SCHEMBL1861180 | 0.80 | ALDH1A1 (0.38) | NR1H2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-1931684-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007017828-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | NR1H2 299/4885ALDH1A1 698/4885FKBP1A 2221/4885 |
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | NR1H2 367/4885ALDH1A1 2770/4885FKBP1A 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.